{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43(7)"],"submitter":["Naveen R"],"pubmed_abstract":["The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively"],"journal":["Rheumatology international"],"pagination":["1265-1275"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10064600"],"repository":["biostudies-literature"],"pubmed_title":["Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey."],"pmcid":["PMC10064600"],"pubmed_authors":["Goswami RP","Distler O","Velikova T","Campagne J","Fonseca JE","Sainaghi PP","Del Papa N","Jain A","Gheita T","Gromova MA","Chinoy H","Orsolini G","Sebastiani M","COVAD Study Group","Patro PS","Venerito V","Zuleta WGR","Danielli MG","Pande AR","Shinjo SK","Parisi S","Milchert M","Cansu DU","Kuwana M","Lilleker JB","Ajmani S","Cavagna L","Aggarwal R","Chowdhury AC","Landon-Cardinal O","Day J","Salim B","Kimura N","Tomaras S","Sebastiani GD","Bommakanti KT","Phatak S","Yoshida A","Silva JAP","Mathew AJ","Nagy-Vincze M","Pandya SC","Shenoy P","Kaneko Y","Gupta V","Limaye V","Gracia-Ramos AE","Maurier F","Shaharir SS","M MM","Hudson M","Saha S","Sato S","Thakare DR","Agarwal V","Chandwar K","Fabiola A","La Torre IG","Pilania RK","Fusaro E","Tehozol EAZ","Giannini M","Gonzalez RA","Sharma A","Gupta L","Serrano JR","Aharonov O","Govoni M","Langguth D","Chatterjee T","Kavadichanda CG","De Angelis R","Makol A","Sen P","Naveen R","Franceschini F","Bocci EB","Quartuccio L","Jagtap K","Traboco LS","Nakashima R","Parodis I","Wibowo SAK","Meyer A","Nune A","Ziade N","Sambataro G","Tan AL","Knitza J","Hoff LS","Needham M","Joshi M","Kardes S","Shukla A","Zimba O","Barman B","Loarce-Martos J","Hmamouchi I","Asranna A","Prieto-Gonzalez S","Pauling JD","Wincup C","Srivastav N","Saavedra MA","Nikiphorou E","Singh YP","Ranjan R"],"additional_accession":[]},"is_claimable":false,"name":"Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.","description":"The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2025-04-04T11:59:29.347Z","creation":"2025-02-19T04:00:49.55Z"},"accession":"S-EPMC10064600","cross_references":{"pubmed":["37000295"],"doi":["10.1007/s00296-023-05310-9"]}}